Omics! Omics!

A computational biologist's personal views on new technologies & publications on genomics & proteomics and their impact on drug discovery

Thursday, January 29, 2026

Sequencer vs. Library Prep Market Structures

›
Something I started pondering as I was prepping my JP Morgan items: the structure of the market for sequencing library prep is very differen...
Wednesday, January 28, 2026

P2 Solo: ONT Extends Support But Not Sales

›
A brief update to the earlier P2 Solo piece - Oxford Nanopore has now announced they will extend their support for the device until 2030, b...
Sunday, January 25, 2026

ONT Axes P2 Solo, Roiling Community

›
Oxford Nanopore has a serious case of user community unrest, triggered by the announcement that the P2 Solo (aka P2s) will be phased out sta...
2 comments:
Thursday, January 22, 2026

JP Morgan 2026 Roundup

›
The J.P. Morgan conference last week was mostly small tidbits of info on the sequencing front, with Element delivering the one big teaser an...
Sunday, January 11, 2026

JPM 2026 Schedule Through A Molecular Tools & Testing Lens

›
The J.P. Morgan Healthcare Conference is this week in San Francisco.  As with every other one, I'm tracking any news remotely from Bosto...
Friday, January 09, 2026

Stalking the Elusive Product Market Fit

›
I had a wonderful breakfast conversation back in November with Arima Genomics Founder (and now President and Chief Operating Officer) Sid Se...
1 comment:
Wednesday, January 07, 2026

Scales of Instrumentation and Automation

›
Back in September I moved into a product role within the automation unit at Ginkgo, where we sell autonomous laboratories.  I'm going to...
3 comments:
›
Home
View web version

About Me

My photo
Keith Robison
Dr. Robison spent 10 years at Millennium Pharmaceuticals working with various genomics & proteomics technologies & working on multiple teams attempting to apply these throughout the drug discovery process. He spent 2 years at Codon Devices working on a variety of protein & metabolic engineering projects as well as monitoring a high-throughput gene synthesis facility. After a brief bit of consulting, he rejoined the cancer drug discovery field at Infinity Pharmaceuticals in May 2009. In September 2011 he joined Warp Drive Bio, a startup applying genomics to natural product drug discovery. In February 2019 he joined Ginkgo Bioworks, a synthetic biology company. Other recurring characters in this blog are his late loyal Shih Tzu Amanda, his current Shih Poo Lily and his now adult son alias TNG (The Next Generation). Dr. Robison can be reached via his Gmail account, keith.e.robison@gmail.com You can also follow him on Twitter as @OmicsOmicsBlog.
View my complete profile
Powered by Blogger.